Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02007512
What this trial is testing

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 247
Testing effectiveness (Phase 2)Looking for participantsNCT07100600
What this trial is testing

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

Who this might be right for
HER2-positive Advanced Breast CancerBrain MetastasesRadiotherapy
Henan Cancer Hospital 224
Not applicableStudy completedNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 204
Not applicableStudy completedNCT06363812
What this trial is testing

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 258
Not applicableUnknownNCT01850628
What this trial is testing

NSABP Biospecimen Discovery Project

Who this might be right for
Breast Cancer
NSABP Foundation Inc 50
Testing effectiveness (Phase 2)Study completedNCT00773344
What this trial is testing

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Who this might be right for
Solid TumorsBreast Cancer
Bristol-Myers Squibb 25
Testing effectiveness (Phase 2)Looking for participantsNCT06450314
What this trial is testing

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
UNICANCER 170
Large-scale testing (Phase 3)Looking for participantsNCT07528716
What this trial is testing

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Who this might be right for
Breast Cancer
Fudan University 280
Not applicableEnded earlyNCT00358098
What this trial is testing

Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AHS Cancer Control Alberta 51
Large-scale testing (Phase 3)UnknownNCT05861830
What this trial is testing

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Who this might be right for
Advanced Breast Cancer
Peking Union Medical College Hospital 80
Large-scale testing (Phase 3)Looking for participantsNCT05063136
What this trial is testing

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 1,979
Not applicableStudy completedNCT04460898
What this trial is testing

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

Who this might be right for
Breast Cancer
Pfizer 195
Not applicableStudy completedNCT07108595
What this trial is testing

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 142
Not applicableUnknownNCT05000736
What this trial is testing

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

Who this might be right for
Hormone Receptor Positive Advanced Breast Cancer
Chinese Academy of Medical Sciences 600
Large-scale testing (Phase 3)Active Not RecruitingNCT03820830
What this trial is testing

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Who this might be right for
Breast Cancer Recurrent
ETOP IBCSG Partners Foundation 405
Post-approval studies (Phase 4)UnknownNCT04767828
What this trial is testing

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

Who this might be right for
TTP
Tianjin Medical University Cancer Institute and Hospital 43
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Large-scale testing (Phase 3)Study completedNCT01566721
What this trial is testing

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 2,577
Not applicableLooking for participantsNCT06930521
What this trial is testing

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

Who this might be right for
Cardiovascular HealthBreast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Women's College Hospital 300
Testing effectiveness (Phase 2)Study completedNCT02756364
What this trial is testing

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Who this might be right for
Breast Neoplasms
Calithera Biosciences, Inc 141
Next Page